NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...

SillaJen Inc. (KOSDAQ:215600) entered into a cooperative research and development agreement (CRADA) with NIH's National Cancer Institute to evaluate the biotech's Pexa-Vec pexastimogene in combination with undisclosed antibodies targeting PD-L1 and cytotoxic T-lymphocyte associated protein...

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...